We have reached a stage whereby many of the superficial
mycoses are treatable with short courses of antifungal drugs. However, the minimum
duration of therapy has still not been well defined and there remain some
mycoses which do not respond to conventional
therapy. It may be possible to introduce more radical approaches to
therapy such as the single-dose oral or topical
therapy for
tinea pedis or short-duration
therapy for
onychomycosis. Amongst these options, topical
therapies still have a part to play in the management of
onychomycosis, and the role of
amorolfine in this respect is of potential value. The ability of the
drug to produce lasting remissions after short courses of treatment is also of great interest. Last, but not least,
amorolfine has an in-vitro spectrum of activity which covers some of the less common cutaneous pathogens, and hence it may prove of benefit in those
infections for which treatment at present is limited.